Document Detail


Treatment with immunosuppressive and disease modifying drugs during pregnancy and lactation.
MedLine Citation:
PMID:  1285866     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Active rheumatic disease may necessitate the treatment of pregnant and lactating patients with disease modifying (DMARD) or immunosuppressive drugs. This review summarizes data from the literature, and attempts to give some recommendations. Possible teratogenic effects of gold, penicillamine, and chloroquine are still disputed. As long as the issue is not settled, it seems prudent to stop using these agents as soon as pregnancy is diagnosed. Hydroxychloroquine has been used by some rheumatologists for treating pregnant patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) without malformations detected in the neonates. Sulphasalazine does not increase the rate of congenital abnormalities. Selected case reports have not shown any teratogenicity of cyclosporine A so far. However, the drug may cause fetal retardation. The use of standard doses of azathioprine does not increase the risk of congenital anomalies. By contrast, the antitumor agents cyclophosphamide, chlorambucil, and methotrexate are possibly teratogenic when given during early pregnancy, but may be less harmful in late pregnancy. Data on the excretion of DMARD and the cytostatic drugs are sparse. Because of insufficient data, breast feeding is not recommended in patients on antimalarials, penicillamine, cyclosporine A, and cytostatic drugs. Intramuscular gold and sulphasalazine seem to impose no major risk on the nursing infant.
Authors:
M Ostensen
Related Documents :
22197126 - Ovarian stimulation and intrauterine insemination in women aged 40years or more.
9804446 - Treating gastro-oesophageal reflux disease during pregnancy and lactation: what are the...
9643396 - Pregnancy and epilepsy.
15143956 - Belgian consensus on recommendations for standards of care for women with epilepsy befo...
9511016 - Biological mechanisms of environmentally induced causes of iugr.
2265596 - Effects of maternal cigarette smoking on ultrasonic measurements of fetal growth and on...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  American journal of reproductive immunology (New York, N.Y. : 1989)     Volume:  28     ISSN:  1046-7408     ISO Abbreviation:  Am. J. Reprod. Immunol.     Publication Date:    1992 Oct-Dec
Date Detail:
Created Date:  1993-03-18     Completed Date:  1993-03-18     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8912860     Medline TA:  Am J Reprod Immunol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  148-52     Citation Subset:  IM    
Affiliation:
Department of Rheumatology, University Hospital of Trondheim, Norway.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Abnormalities, Drug-Induced / etiology*
Anti-Inflammatory Agents, Non-Steroidal / adverse effects,  therapeutic use*
Autoimmune Diseases / drug therapy*
Chloroquine / adverse effects,  therapeutic use
Female
Fetus / drug effects
Humans
Immunosuppressive Agents / adverse effects,  therapeutic use*
Infant, Newborn
Lactation*
Milk, Human / chemistry
Pregnancy
Pregnancy Complications / drug therapy*
Pregnancy Outcome
Prenatal Exposure Delayed Effects
Rheumatic Diseases / drug therapy*
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Immunosuppressive Agents; 54-05-7/Chloroquine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  NSAIDs: maternal and fetal considerations.
Next Document:  The use of low dose aspirin in pregnancy.